Hedge Fund - Armistice Capital

Hedge fund managers and other investors had identified investment opportunities prior to the broader market pullback in August, so why not acquire more shares on the cheap? Most hedge funds have been ...

In two separate filings with the U.S. Securities and Exchange Commission, Armistice Capital, led by Steven Boyd, disclosed massively cutting its activist stake in Spectrum Pharmaceuticals Inc.

Is it a good time to buy shares of Ascendis Pharma A/S (NASDAQ:ASND)? Jacob Gottlieb thinks so, since his fund, Visium Asset Management, has significantly increased its holding in the company recently...

According to a recent filing with the Securities and Exchange Commission, Steven Boyd's Armistice Capital initiated a position in Pernix Therapeutics Holdings Inc (NASDAQ:PTX) by acquiring some 3.4 million...